About this event

Antibody Industrial Symposium (AIS) — 14th Edition (AIS2026) | Description & Audience Research Profile

1) Event overview (what AIS2026 is)

The Antibody Industrial Symposium (AIS) is an international congress focused on the latest advances and associated challenges in therapeutic antibodies and their derivatives, recombinant proteins, and other biomedicines. AIS2026 is jointly organized by LabEx MAbImprove and MabDesign.

The symposium is positioned as a cross-functional industry and science platform where researchers, industry leaders, medical professionals, and policymakers converge. The program combines: keynote lectures, dynamic pitch talks showcasing innovative projects, and industry presentations from leading pharmaceutical entities.

2) Real dates, venue, city, and country (from official site content)

• Event name: 14th Antibody Industrial Symposium (AIS2026)
• Dates: June 30 – July 1, 2026
• Location: CORUM Congress Center
• City: Montpellier
• Country: France

3) Pre-event and co-located content (what extends AIS2026)

Exclusive pre-event (June 29, 2026)

AIS2026 includes an exclusive pre-event hosted by Evotec on June 29th, 2026: “From Antibody Discovery to IND: Advancing Biologics in Oncology”. This pre-event is described as a high-level scientific session offering deep insights into biologics development.

Exclusive INITS SMO site visit (June 29, 2026)

AIS2026 also includes an exclusive INITS SMO site visit on June 29th, 2026. The site is described as a 3,200 m² multiproduct and flexible GMP biomanufacturing facility, and the visit is positioned as a behind-the-scenes look at shared manufacturing capabilities.

Co-located event: AFSSI Connexions

For the first time, AIS will host AFSSI Connexions at the same venue and time, creating additional ecosystem reach among innovative biotech service providers.

4) 1️⃣ Who attends (BUYERS / ATTENDEES)

AIS2026 is not purely a mass-market conference; it is structured around the therapeutic antibody and biomedicines value chain. That means attendance typically blends technical decision makers, commercial/product-side leaders, and ecosystem stakeholders.

Top attendee/buyer archetypes we expect to find:

• Therapeutic antibody & biologics R&D leadership (discovery, translational, program leadership)
• Clinical-stage/clinical development leaders involved in biologics programs
• Biomanufacturing and process development stakeholders (especially relevant due to the INITS SMO site visit)
• External innovation & collaboration decision makers (partners, alliances, BD, licensing, scientific partnerships)
• Medical professionals and translational experts aligned to immunology/oncology and antibody modalities
• Policymakers and ecosystem representatives focused on enabling frameworks and collaboration
• Service providers and enabling technology companies (CDMO/CRO, analytics, formulation, antibodies engineering tools)

AIS also explicitly states that it provides networking opportunities where companies can showcase products and technologies and foster high-impact business collaborations—so exhibitors and sponsors are an important buyer layer.

5) 2️⃣ Where the show is happening + attendee geographic origin

Venue: CORUM Congress Center in Montpellier, France.

For geographic origin, AIS is described as an international congress. While the official text confirms the location and international character, it does not provide exact regional breakdowns. Practically, we would position the expected attendee mix as:

• Strong European presence (because the event is held in France and includes co-located French biotech ecosystem content)
• International participation from global pharma and biotech organizations with active therapeutic antibody pipelines
• Cross-border ecosystem engagement from enabling technology providers and services aligned to antibody development through clinical phases

If we need a strict “country-by-country origin” model for targeting, we should validate it with a post-event report, exhibitor/sponsor geography, or attendee registration insights.

6) 3️⃣ Audience reach (Local / National / Global)

Based on the official positioning—prestigious international congress and spanning multiple industry categories from R&D to clinical phases—AIS2026 should be treated as: Global reach with a Europe-centered venue footprint.

The symposium also includes a pre-event and facility site visit (June 29) and a co-located ecosystem event (AFSSI Connexions), which typically increases breadth beyond a single modality community and pulls in additional service and manufacturing stakeholders.

7) 4️⃣ Sample buyer company names (BUYERS ONLY) + websites

Below is a curated set of buyer-style target companies that are active in therapeutic antibodies/biologics and/or enabling services relevant to antibody development and industrialization. These are designed to align to roles we target in Apollo-style research categories (without mentioning any tools).

Best “top priority” buyer targets to start with

If we need a short opening list for client outreach, we recommend focusing first on: Evotec, Roche (Genentech), Pfizer, AstraZeneca, and Lonza. This set covers discovery-to-IND, clinical-stage development, and industrial/biomanufacturing needs—directly aligned with AIS scope.

8) 5️⃣ Job profiles, industries & event type

Best job profiles to target (AIS-relevant buyer roles)

• Biologics / Therapeutic Antibody Program Leaders (discovery, translational, and clinical program ownership)
• Director/VP, Antibody Discovery & Engineering
• Translational Medicine Leaders (IND-facing readiness and development decisions)
• Clinical Development Leaders (clinical-stage antibody derivatives and biologics)
• Bioprocess/Process Development & Manufacturing Leaders
• CDMO/CDMO Business Development Leaders (partnership and manufacturing strategy)
• Partnerships & Alliance Managers (collaboration formation for antibody programs)
• Quality/Compliance leadership for GMP manufacturing (especially relevant given the site visit)
• Medical affairs / Medical professional leadership for therapy positioning and evidence exchange
• Service provider account leadership at CROs/tools enabling antibody development

Industries to use (mapping to your Apollo industry list categories)

AIS sits primarily in the following industry categories (from your provided list). We prioritize them because they match therapeutic antibody R&D, biologics manufacturing, and development services:

• Pharmaceuticals
• Biotechnology
• Research
• Medical Practice (selectively, for medical/professional involvement)
• Hospital & Health Care (selectively, for clinical-facing professionals)
• Events Services (only for internal event coordination roles; limited relevance)
• Medical Devices (only if exhibitors include enabling technologies that overlap with lab/clinical instrumentation)

Event type (based on official content)

AIS2026 is best categorized as a biopharma industry congress covering therapeutic antibodies and biologics, spanning from R&D through clinical phases, with explicit networking and partner showcase components.

9) 6️⃣ Estimated attendance (expected total footfall)

The official website content we received does not include a numeric estimate for delegates/exhibitors/speakers/footfall for AIS2026. In that case, we leave this field as not specified rather than guessing.

Estimated attendance: (Not provided on the provided official text)

10) 7️⃣ Key focus areas & buyer engagement

AIS2026 is designed around industrially relevant topics in therapeutic antibodies and associated biomedicines. The official content highlights both scientific sessions and industry-oriented presentations.

Key focus areas (what buyers will care about)

• Therapeutic antibody R&D advancements (and derivative modalities)
• Recombinant protein development challenges
• Transition from R&D into clinical phases (development readiness and program execution)
• IND pathway and biologics development strategy (explicitly referenced by the Evotec pre-event)
• Industrialization and GMP manufacturing ecosystem (explicitly supported by the INITS SMO site visit)
• Business collaboration and technology showcase (networking opportunities for high-impact partnerships)
• Industry presentations from leading pharmaceutical entities
• Broader biotech service provider collaboration (via AFSSI Connexions co-location)

How buyers are likely to engage

• Agenda-led engagement: keynote and pitch talks where R&D and industrial partners align on near-term priorities
• Partnership intent: sponsor/exhibitor and networking designed for collaboration formation
• Operational depth: site visits and manufacturing-adjacent discussions that attract production/process decision makers
• Cross-functional attendance: discovery, translational, clinical, and manufacturing roles in one venue

11) 8️⃣ Client-product fit note (we need your client website to refine best buyers)

To identify the best buyer matches for your exact client requirement, we need the client’s product context. Your instruction specifies we should ask for the client website and then determine the best buyer profiles from event attendees/exhibitors.

Please share your client website. Once we review it, we will produce:

• the most relevant buyer segments for that product category
• the highest-fit job titles (e.g., discovery vs. manufacturing vs. clinical vs. BD)
• a prioritized buyer company list that best aligns to what the client actually sells/serves

Until we have the website, we can only provide a general AIS-aligned buyer profile (above). After we get the site, we will narrow down to the “best buyers” for your specific use case.

12) 9️⃣ Summary (how we would position AIS2026 for buyer targeting)

• Why this event is strong: AIS2026 directly covers therapeutic antibodies and biomedicines from R&D into clinical phases, with industry collaboration emphasis.
• Why it attracts buyers: the audience includes program leaders, development and manufacturing stakeholders, and ecosystem service providers.
• Why the venue matters: held in Montpellier at CORUM Congress Center, with an added pre-event and a GMP facility site visit that increases depth of manufacturing relevance.
• How we target: we build buyer lists around antibody/biologics development roles and industrialization decision makers, then refine based on your client’s website.

Quick “Client Website Needed” Request

To finalize the “best buyers” for your client requirement, please send: your client’s website URL and (if available) a 1–2 sentence summary of what the client sells (e.g., antibody discovery tooling, CDMO service, analytics, clinical solutions, etc.).